Lord, Abbett & Co
MLYS icon

Lord, Abbett & Co’s Mineralys Therapeutics MLYS Stock Holding History

Lord, Abbett & Co’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-300,913
Closed -$8.15M – 605
2026
Q1 		$8.15M Sell
300,913
-11,483
-4% -$337K 0.03% 390
2025
Q4 		$11.3M Buy
+312,396
New +$12.5M 0.03% 363

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Lord, Abbett & Co's MLYS Position: Q2 2026 in Review

Lord, Abbett & Co sold out of Mineralys Therapeutics (MLYS) in Q2 2026, closing a stake of 300,913 shares — an estimated $8.15M sold.

Lord, Abbett & Co first reported a position in MLYS in Q4 2025 and held it in 2 quarters. The position peaked at $11.3M in Q4 2025. 226 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

  • Lord, Abbett & Co reported no remaining Mineralys Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Lord, Abbett & Co sold 300,913 Mineralys Therapeutics shares in Q2 2026, an estimated $8.15M.
  • Lord, Abbett & Co first reported a position in Mineralys Therapeutics in Q4 2025 and held it in 2 quarters.
  • Lord, Abbett & Co's Mineralys Therapeutics position peaked at $11.3M in Q4 2025.
  • 226 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Lord, Abbett & Co's 13F filing for Q2 2026, filed 14 Aug 2026.